Bipolar disorder treatment for Coral Springs — the diagnosis primary care misses.

RECO Integrated Psychiatry is a 35-minute drive from Coral Springs via the Sawgrass Expressway, close enough that Eagle Trace, Parkland Isles, and Heron Bay families can access specialist psychiatry without a residential program. The practice runs lithium, lamotrigine, and second-generation antipsychotic protocols with lab-monitoring infrastructure most primary care can't sustain. Diagnosis is load-bearing: misdiagnosis of bipolar II as unipolar depression drives most treatment failures, and RECO's evaluation is built to catch it.

Coral Springs sits 25 miles inland from RECO Integrated Psychiatry’s Delray Beach office — a 35-minute drive via the Sawgrass Expressway and I-95 that puts specialist-level outpatient psychiatry within reach of Eagle Trace, Hidden Hammocks, Parkland Isles, Cypress Run, and Heron Bay. For adults navigating bipolar disorder, that distance is the difference between primary-care medication management and a practice that runs lithium, lamotrigine, and second-generation antipsychotic protocols the way the evidence base requires. Access to bipolar disorder treatment at this level of specificity is not the norm in northwest Broward, which is why the drive is worth it.

Bipolar I, bipolar II, and bipolar spectrum — why the diagnosis drives everything

The single most consequential decision in bipolar treatment is the diagnostic one, and it is the decision most often missed. Bipolar I requires at least one manic episode — seven days of elevated or irritable mood with functional impairment or hospitalization, or a shorter course when psychotic features are present. Bipolar II requires a hypomanic episode of at least four days plus a full major depressive episode; the depressive burden is what usually brings people to care, which is why bipolar II is routinely mislabeled as treatment-resistant unipolar depression. Bipolar spectrum captures cyclothymia, BP-NOS, and antidepressant-induced hypomania — presentations with clear cyclicity that do not meet full duration criteria.

Distinguishing these categories changes the pharmacology entirely. Bipolar I responds to combination regimens built around lithium or valproate with a second-generation antipsychotic. Bipolar II depression responds to lamotrigine and quetiapine but not straightforwardly to lithium monotherapy. Bipolar spectrum presentations require cautious antidepressant use with mood-stabilizer cover to avoid triggering hypomania.

RECO’s evaluation uses the MDQ, HCL-32, structured hypomania history, and prospective mood charting across the first eight weeks to make the call. Starting the wrong medication — most commonly an SSRI monotherapy in an unrecognized bipolar II — is the most common driver of the “nothing has worked” story.

Lithium — the treatment we take seriously when others don’t

Lithium remains the most effective long-term mood stabilizer in bipolar disorder and the only psychotropic with replicated evidence for suicide reduction. Baseline workup includes TSH, creatinine, calcium, CBC, and a pregnancy test where relevant. Maintenance target serum levels sit at 0.6-1.0 mEq/L, drawn 12 hours post-dose, quarterly early in treatment and semiannually once stable. Ongoing monitoring covers thyroid function, renal function, weight, and calcium — a protocol that takes minutes per visit when it is built into the workflow.

Many outpatient clinicians avoid lithium because the monitoring feels burdensome or because a single case of toxicity in training has made them cautious. RECO’s practice runs lithium at scale, which means the operational infrastructure — standing lab orders, automated recall for level draws, dose adjustment protocols for NSAID and ACE-inhibitor interactions — is already in place.

For clients who tolerate lithium, the effect on episode frequency, hospitalization risk, and long-term mortality justifies the monitoring burden. It is not the right medication for everyone, but the decision should turn on clinical grounds, not on whether the practice is set up to prescribe it.

Second-generation antipsychotics and where they fit

Second-generation antipsychotics carry FDA approvals across specific bipolar phases, and choice is driven by which pole a client is in and which side-effect profile they can live with over years. Quetiapine holds approvals across bipolar depression, mania, and maintenance. Lurasidone is approved for bipolar depression with a favorable metabolic profile. Aripiprazole and cariprazine are approved for mania and maintenance, with cariprazine also carrying a bipolar depression indication. Olanzapine and the olanzapine-fluoxetine combination are effective across mania and bipolar depression but carry substantial metabolic burden. Risperidone remains an option for acute mania.

Metabolic monitoring — weight, waist circumference, HbA1c, fasting lipids, blood pressure — is standard at baseline, twelve weeks, and annually thereafter. Prolactin and movement-disorder screening (AIMS) are added where the medication class and cumulative exposure warrant. The clinical judgment is not “which antipsychotic is best” but which agent fits the current phase, the client’s prior response history, and the tolerability profile they can sustain.

Lamotrigine, valproate, and the anticonvulsant options

Lamotrigine carries the strongest evidence for bipolar II depression and for maintenance where depression is the predominant pole. Titration is deliberately slow — 25 mg for two weeks, 50 mg for two weeks, then step increases to a 200 mg target — because the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis correlates with rate of dose escalation. Rash-workflow triage, dose halving with valproate co-administration, and oral contraceptive interaction management are protocol-driven at RECO.

Valproate is effective in mania and mixed states, with target serum levels of 50-125 mcg/mL and monitoring of LFTs, platelets, and ammonia where clinically indicated. It is teratogenic and is generally avoided in women of reproductive age unless alternatives have failed and contraception is documented in the chart. Carbamazepine and oxcarbazepine sit further down the algorithm with their own monitoring — CBC, sodium, LFTs — and CYP450 induction that complicates polypharmacy.

Each anticonvulsant has a defined monitoring protocol, and RECO’s practice runs each of them rather than defaulting to whichever medication the last prescriber happened to be comfortable with.

What to expect on your first visit

Initial evaluations run 60-75 minutes with a board-certified psychiatrist. The visit covers full psychiatric history, family history of mood disorders and completed suicide, prior medication trials with response and side-effect data, substance use screening, medical comorbidities, and structured rating scales — MDQ and HCL-32 for hypomania, PHQ-9 for depression, GAD-7 for anxiety, and ASRS where ADHD sits on the differential. Records from prior prescribers are requested in advance so the visit can focus on the diagnostic and treatment question rather than history reconstruction.

Where the diagnosis is clear, treatment begins the same day with a defined follow-up cadence, lab orders, and a written safety plan. Where the diagnosis is uncertain, an eight-week prospective mood-charting period precedes commitment to a long-term regimen. Family members can be included with the client’s written consent — collateral history routinely clarifies hypomanic episodes the client under-recognizes.

Insurance and admissions from Coral Springs

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Coverage for outpatient psychiatric evaluation, medication management, and standard lab monitoring is generally straightforward under mental health parity once benefits are verified. The admissions team completes a benefits check before the first appointment so cost expectations are clear before care begins.

For established clients on stable regimens, telepsychiatry follow-ups are available; initial evaluations and any lab-linked medication changes are conducted in person at the Delray Beach office, a 35-minute drive from most Coral Springs neighborhoods.

Serving residents of: Eagle Trace, Hidden Hammocks, Parkland Isles, Cypress Run, Heron Bay.